rp NASDAQ:XERS - Stock Price, News, & Analysis for Xeris Pharmaceuticals

NASDAQ:XERS - Xeris Pharmaceuticals Stock Price, News, & Analysis

$10.26
+0.66 (+6.87 %)
(As of 06/17/2019 01:06 PM ET)
Today's Range
$9.45
Now: $10.2650
$10.2650
50-Day Range
$7.25
MA: $10.83
$12.60
52-Week Range
$6.85
Now: $10.2650
$27.98
Volume66,166 shs
Average Volume276,467 shs
Market Capitalization$276.54 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Xeris Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:XERS
CUSIPN/A
CIKN/A
Phone844-445-5704

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.46 million
Book Value$3.61 per share

Profitability

Net Income$-60,080,000.00
Net Margins-2,997.96%

Miscellaneous

Employees90
Market Cap$276.54 million
Next Earnings Date8/12/2019 (Estimated)
OptionableNot Optionable

Receive XERS News and Ratings via Email

Sign-up to receive the latest news and ratings for XERS and its competitors with MarketBeat's FREE daily newsletter.

Xeris Pharmaceuticals (NASDAQ:XERS) Frequently Asked Questions

What is Xeris Pharmaceuticals' stock symbol?

Xeris Pharmaceuticals trades on the NASDAQ under the ticker symbol "XERS."

How were Xeris Pharmaceuticals' earnings last quarter?

Xeris Pharmaceuticals Inc (NASDAQ:XERS) announced its earnings results on Thursday, May, 9th. The company reported ($1.07) EPS for the quarter, missing analysts' consensus estimates of ($0.76) by $0.31. The firm had revenue of $0.25 million for the quarter, compared to analysts' expectations of $0.30 million. Xeris Pharmaceuticals had a negative net margin of 2,997.96% and a negative return on equity of 75.93%. View Xeris Pharmaceuticals' Earnings History.

When is Xeris Pharmaceuticals' next earnings date?

Xeris Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, August 12th 2019. View Earnings Estimates for Xeris Pharmaceuticals.

What price target have analysts set for XERS?

4 brokerages have issued 1 year price objectives for Xeris Pharmaceuticals' shares. Their forecasts range from $23.00 to $27.00. On average, they anticipate Xeris Pharmaceuticals' share price to reach $24.50 in the next year. This suggests a possible upside of 138.7% from the stock's current price. View Analyst Price Targets for Xeris Pharmaceuticals.

What is the consensus analysts' recommendation for Xeris Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xeris Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Xeris Pharmaceuticals.

What are Wall Street analysts saying about Xeris Pharmaceuticals stock?

Here are some recent quotes from research analysts about Xeris Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Xeris Pharmaceuticals, Inc. produces peptides, proteins, antibodies, molecules, auto-injectors, multi-dose pens and infusion pumps to treat endocrine and metabolic diseases. The company's proprietary formulation technologies consist of XeriSol (TM) and XeriJect(TM). Xeris Pharmaceuticals, Inc. is based in Chicago, United States. " (1/12/2019)
  • 2. Mizuho analysts commented, "We continue to see Xeris’ glucagon rescue pen as a superior option for the treatment of severe hypoglycemia from a product profile perspective, as we believe there is a higher probability of successfully delivering the full dose to the patient in an emergency situation. Management believes the product could do much better than a 50% market share." (12/4/2018)

Has Xeris Pharmaceuticals been receiving favorable news coverage?

Media coverage about XERS stock has trended somewhat positive this week, according to InfoTrie. The research firm identifies negative and positive press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Xeris Pharmaceuticals earned a media sentiment score of 1.4 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for Xeris Pharmaceuticals.

Are investors shorting Xeris Pharmaceuticals?

Xeris Pharmaceuticals saw a increase in short interest during the month of May. As of May 31st, there was short interest totalling 1,560,900 shares, an increase of 18.2% from the April 30th total of 1,320,200 shares. Based on an average trading volume of 227,500 shares, the days-to-cover ratio is presently 6.9 days. Approximately 7.0% of the company's stock are short sold. View Xeris Pharmaceuticals' Current Options Chain.

Who are some of Xeris Pharmaceuticals' key competitors?

What other stocks do shareholders of Xeris Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xeris Pharmaceuticals investors own include Pareteum (TEUM), TG Therapeutics (TGTX), GAP (GPS), Abeona Therapeutics (ABEO), Biocept (BIOC), Cytori Therapeutics (CYTX), Flexion Therapeutics (FLXN), GlycoMimetics (GLYC), Omeros (OMER) and Rigel Pharmaceuticals (RIGL).

Who are Xeris Pharmaceuticals' key executives?

Xeris Pharmaceuticals' management team includes the folowing people:
  • Mr. Paul R. Edick, Pres, CEO & Chairman (Age 63)
  • Mr. Barry M. Deutsch, Chief Financial Officer (Age 54)
  • Mr. John P. Shannon, Exec. VP & COO (Age 57)
  • Dr. Steven J. Prestrelski, Co-Founder & Chief Scientific Officer (Age 55)
  • Ms. Allison Wey, Sr. VP of Investor Relations & Corp. Communications

When did Xeris Pharmaceuticals IPO?

(XERS) raised $75 million in an initial public offering on Thursday, June 21st 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Mizuho Securities was co-manager.

Who are Xeris Pharmaceuticals' major shareholders?

Xeris Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Redmile Group LLC (11.14%), FMR LLC (11.00%), Marshall Wace LLP (0.09%), Rhumbline Advisers (0.09%), Marshall Wace North America L.P. (0.03%) and BNP Paribas Arbitrage SA (0.02%). Company insiders that own Xeris Pharmaceuticals stock include Beth Hecht, James E Flynn, Palmetto Partners, Ltd, Paul R Edick, Redmile Group, Llc and Steven Prestrelski. View Institutional Ownership Trends for Xeris Pharmaceuticals.

Which major investors are buying Xeris Pharmaceuticals stock?

XERS stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Redmile Group LLC, Marshall Wace LLP, Rhumbline Advisers, Marshall Wace North America L.P. and BNP Paribas Arbitrage SA. Company insiders that have bought Xeris Pharmaceuticals stock in the last two years include Beth Hecht, James E Flynn, Palmetto Partners, Ltd, Paul R Edick and Redmile Group, Llc. View Insider Buying and Selling for Xeris Pharmaceuticals.

How do I buy shares of Xeris Pharmaceuticals?

Shares of XERS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Xeris Pharmaceuticals' stock price today?

One share of XERS stock can currently be purchased for approximately $10.2650.

How big of a company is Xeris Pharmaceuticals?

Xeris Pharmaceuticals has a market capitalization of $276.54 million and generates $2.46 million in revenue each year. The company earns $-60,080,000.00 in net income (profit) each year or ($4.99) on an earnings per share basis. Xeris Pharmaceuticals employs 90 workers across the globe.View Additional Information About Xeris Pharmaceuticals.

What is Xeris Pharmaceuticals' official website?

The official website for Xeris Pharmaceuticals is http://www.xerispharma.com/.

How can I contact Xeris Pharmaceuticals?

Xeris Pharmaceuticals' mailing address is 180 N. LaSalle Street Suite 1810, Chicago IL, 60601. The company can be reached via phone at 844-445-5704 or via email at ir@xerispharma.com.


MarketBeat Community Rating for Xeris Pharmaceuticals (NASDAQ XERS)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  46 (Thanks for Voting!)
Underperform Votes:  56 (Thanks for Voting!)
Total Votes:  102
MarketBeat's community ratings are surveys of what our community members think about Xeris Pharmaceuticals and other stocks. Vote "Outperform" if you believe XERS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XERS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/17/2019 by MarketBeat.com Staff

Featured Article: What is a Futures Contract?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel